61895-53-2

Upstream product

• 1074-82-4 potassium phtalimide 
• 623-25-6 p-Xylylene dichloride 
• 136918-14-4 phthalimide 

Downstream Products

• 309920-74-9 [5-(4-aminomethyl-benzyloxy)-naphthalen-1-yloxy]-acetic acid tert-butyl ester 
• 1452863-21-6 N-{4-([4-(2-methoxyphenyl)piperazin-1-yl]methyl)benzyl}phthalimide 
• 1452863-35-2 N-{4-([4-(2-methoxyphenyl)piperazin-1-yl]methyl)benzyl}phthalimide hydrochloride 
• 733726-67-5 N-{4-([4-(2-methoxyphenyl)piperazin-1-yl]methyl)benzyl}acetamide 
• 1219278-65-5 BF₄^(1-)*C₃₂H₃₆N₅O₃S⁽¹⁺⁾ 
• 1219278-59-7 BF₄^(1-)*C₂₉H₃₈N₅O₃S⁽¹⁺⁾ 
• 1219278-52-0 BF₄^(1-)*C₂₉H₃₂N₅OS⁽¹⁺⁾ 
• 1219278-46-2 BF₄^(1-)*C₂₈H₃₀N₅OS⁽¹⁺⁾ 
• 1219278-39-3 BF₄^(1-)*C₂₆H₃₄N₅OS⁽¹⁺⁾ 
• 1219278-27-9 BF₄^(1-)*C₂₅H₃₂N₅OS⁽¹⁺⁾ 
• 1219278-22-4 BF₄^(1-)*C₂₂H₂₆N₅OS⁽¹⁺⁾ 
• 1219278-15-5 BF₄^(1-)*C₂₂H₂₆N₅OS⁽¹⁺⁾ 
• 1219278-10-0 BF₄^(1-)*C₂₁H₂₄N₅OS⁽¹⁺⁾ 
• 1219278-02-0 BF₄^(1-)*C₂₄H₂₉N₄O₃⁽¹⁺⁾ 

Relevant academic research and scientific papers

New arylpiperazines with flexible versus partly constrained linker as serotonin 5-HT1A/5-HT7 receptor ligands

A series of new long-chain arylpiperazine (LCAP) derivatives with flexible and partly constrained alkyl linker were synthesized and investigated in vitro as potential serotonin 5-HT1A and 5-HT7 receptor ligands. The compounds were prepared by a two-step procedure using naphthalimide and 2H-1,3-benzoxazine-2,4(3H)-dione as imides, and 1-(2-methoxyphenyl)piperazine (o-OMe-PhP) and 1,2,3,4-tetrahydroisoquinoline (THIQ) as amine pharmacophores. Modifications of the spacer structure included introduction of flexible penta- and hexamethylene chains as well as partly constrained m- and p-xylyl moieties. In general, the new compounds were more active at the 5-HT1A than at the 5-HT7 receptor, and the o-OMe-PhP derivatives displayed higher affinities than their respective THIQ analogs. The spacer modifications had little effect on the observed in vitro activities. Within the o-OMe-PhP series, except for a small binding reduction for ligands containing the m-xylyl moiety, there was no substantial change in the compounds' potency at both receptors, while for the THIQ derivatives a clear structure-activity relationship was visible only for the interaction of the compounds with the 5-HT7 receptor, which strongly favored flexible analogs. New LCAP derivatives with flexible and partly constrained alkyl linker were tested as potential serotonin 5-HT1A and 5-HT7 receptor ligands. The spacer structure was modified by introduction of flexible penta- and hexamethylene chains and partly constrained m- and p-xylyl moieties. The new compounds were more active at the 5-HT1A than at the 5-HT7 receptor. o-OMe-PhP derivatives displayed higher affinities than their respective THIQ analogs. The spacer modifications had little effect on the observed in vitro activities. Copyright

Traceless approach for the synthesis of 3,5-disubstituted thiohydantoins on functionalized ionic-liquid support

A traceless approach for the synthesis of 3,5-disubstituted thiohydantoins on a novel functionalized ionic-liquid support, 5, is described. Acylation of benzylamine functionalized ionic-liquid support with amino acids yielded ionic-liquid-supported amino acids, which reacted with isothiocyanates to afford ionic-liquid-supported thioureas. Following intramolecular cyclization cleavage from the ionic-liquid support by trifluoroacetic acid (TFA), the desired 3,5-disubstituted thiohydantoins were obtained in good yields and purities. The efficiency of this ionic-liquid-phase strategy facilitated isolation and analysis of intermediates and removal of excess reagents and by-products during the reaction process.

S-adenosyl methionine decarboxylase inhibitors

The adenosine derivatives represented by the following formula: STR1 and the pharmaceutically acceptable salts thereof wherein R is H or C1 -C7 alkyl, Q is the moiety of the formula STR2 wherein V is H or --COOH X is H, F, Cl, Br, and Z is H, F, Cl, or Br. These compounds are inhibitors of S-adenosylmethione decarboxylase and are useful for treating parasitic infections.

5'-amine substituted adenosine analogs as immunosuppressants

The present invention relates to a method of effecting immunosuppression in a patient in need thereof comprising administering to said patient an effective immunosuppressive amount of certain 5'-amine substituted adenosine analogs.